-+ 0.00%
-+ 0.00%
-+ 0.00%

Melisron (TASE:MLSR) Trades At A P E Discount, Is The Upside Already Priced In?

Simply Wall St·09/20/2026 16:30:29
Listen to the news

Melisron (TASE:MLSR) sits in focus after recent trading data showed a slight decline of 0.6% in the latest session, drawing attention to how its broader return profile stacks up for long term holders.

Recent trading has been soft, with the last close at ₪405.0 and the share price slipping over the past week and year to date. Even so, total shareholder return over one, three and five years remains firmly positive, suggesting longer term holders have still seen meaningful gains despite fading short term momentum.

Compare Melisron's softer recent moves with other real estate plays by scanning our hand picked list of solid balance sheet and fundamentals (198 results) for ideas that combine resilience and fundamental strength.

That combination of soft recent trading and strong multi year gains puts Melisron at an interesting crossroads. Has most of the rerating already played out, or does the current price still leave meaningful upside on the table?

Price-to-Earnings of 11.1x: Is it justified?

In simple terms, Melisron trades on a P/E of 11.1x, which is below several local benchmarks even after the recent share price softness around ₪405.

The P/E multiple compares what investors are paying for each unit of current earnings. For a commercial real estate group like Melisron, it provides a quick read on how the market is weighing its profit stream against other listed businesses in Israel.

With earnings forecast to grow 9.6% per year and five-year historical profit growth of 9.3% a year, the current earnings-based pricing suggests the market is not assigning a premium for that profile. Earnings quality is affected by a ₪1.2b one-off gain and net profit margins that recently eased from 72.8% to 71.5%, which can make headline profitability look stronger than ongoing cash generation. This is especially relevant when debt is not well covered by operating cash flow and funding relies fully on external borrowing.

The comparison set is clear. Melisron trades on 11.1x earnings compared with 13.4x for the Israel real estate industry, 13.6x for peers, and 14.8x for the broader market, which represents a meaningful discount across all three groups.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Earnings of 11.1x (UNDERVALUED).

Still, softer year to date returns and reliance on external borrowing mean that any hit to rental demand or funding costs could quickly challenge the current Melisron rerating story.

Find out about the key risks to this Melisron narrative.

Another view on Melisron's value

The P/E of 11.1x suggests Melisron looks inexpensive next to local peers, yet the SWS DCF model flags something very different. On that measure, the share price of ₪405 sits well above an estimated future cash flow value of ₪37.47, which implies the stock screens as overvalued on a cash basis.

For investors who lean on cash flow rather than earnings, that sort of gap raises a blunt question: Is the market fairly pricing long term rental income resilience, or are expectations already stretched enough to limit the payoff from here?

Look into how the SWS DCF model arrives at its fair value.

MLSR Discounted Cash Flow as at Sep 2026
MLSR Discounted Cash Flow as at Sep 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Melisron for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 180 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Unclear where Melisron really lands after all of this? Take a moment to review the full picture for yourself, including the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Melisron?

If Melisron has you thinking harder about valuation and risk, do not stop with a single ticker. Use the Simply Wall St Screener to line up your next watchlist upgrades.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.